Cholangiocarcinoma: bridging the translational gap from preclinical to clinical development and implications for future therapy.

ABSTRACT: Introduction: Cholangiocarcinoma (CCA) is a devastating liver tumor with a poor prognosis. While less than 50% of the patients with CCA may benefit from surgical resection, the rest undergoes chemotherapy with disappointing results (mean survival <2 years). Alternative pharmacological treatments are needed to improve the outcomes in patients with CCA.Areas covered: In this review, we discuss CCA-related (1) experimental systems used in preclinical studies; (2) pharmacological targets identified by genetic analysis; (3) results obtained in preliminary trials in human with their pros and cons; and (4) possible targeting of endocrinal modulation. A PubMed bibliographic search matching the term 'cholangiocarcinoma' with 'experimental model', 'preclinical model', 'genetic target',

SUBMITTER: Baiocchi L 

PROVIDER: S-EPMC8441992 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature